From Libre Pathology
Jump to: navigation, search

Bortezomib is a proteasome inhibitor to treat multiple myeloma and mantle cell lymphoma. The substance prevents degradation of pro-apoptotic factors, resulting activation of programmed cell death in neoplastic cells. [1]


  1. Curran, MP.; McKeage, K. (2009). "Bortezomib: a review of its use in patients with multiple myeloma.". Drugs 69 (7): 859-88. doi:10.2165/00003495-200969070-00006. PMID 19441872.